Haploinsufficiency vs Dominant-Negative
Log in to starLast updated 3mo ago
Log in to add personal notes on this page.
Autosomal dominant disease can be caused by several distinct molecular mechanisms. The two most clinically central are haploinsufficiency and dominant-negative effects. Both involve a single mutant allele producing disease in a heterozygote, but the mechanism (and therefore the predicted variant spectrum, severity, and therapeutic strategy) is different. Two other dominant mechanisms, gain-of-function and toxic gain-of-function, round out the framework.
1. Haploinsufficiency
- Mechanism: One functional allele produces only ~50% of the normal protein dose, which is insufficient for normal function.
- Variant types that cause it: null variants (nonsense, frameshift, large deletion, splice-disrupting). Anything that abolishes one allele's protein product.
- Gene categories prone to it: dose-sensitive transcription factors, structural proteins where stoichiometry matters, tumor suppressors (in the germline), and any haplosufficient gene whose threshold sits above the 50% mark.
- Examples: PAX6 (aniridia), SOX9 (campomelic dysplasia), TBX5 (Holt-Oram), NSD1 (Sotos syndrome), many tumor suppressors in their germline state (e.g., NF1, TSC1/2, RB1, BRCA1/2, though these also need a somatic second hit for tumor formation).
- Predicting it: if the gene's mutation spectrum is dominated by null variants (nonsense, frameshift, whole-gene deletion), haploinsufficiency is the working hypothesis.
2. Dominant-Negative (Antimorphic)
- Mechanism: The mutant protein is made and actively interferes with the wild-type protein's function. Total functional output drops below 50%, sometimes far below, because the mutant "poisons" the wild-type.
- Variant types that cause it: missense variants in critical functional or interaction domains. Variants that preserve the protein but corrupt its activity.
- Gene categories prone to it: multimeric proteins (homodimers, homotrimers, larger complexes) where one bad subunit corrupts the whole assembly.
- Examples: COL1A1/COL1A2 in osteogenesis imperfecta, where a single mutant pro-α chain incorporated into the triple helix destabilizes the entire trimer (often more severe than a null variant where the mutant chain is absent and only normal chains form helices). Other examples: KRT5/KRT14 in epidermolysis bullosa simplex, CRYBB1 in cataracts, dominant-negative TP53 variants in Li-Fraumeni.
- Predicting it: if the gene's mutation spectrum is dominated by missense variants in functional domains with relative paucity of null alleles, and especially if heterozygous null variants are less severe than missense variants (the classic "null is milder than missense" signature), dominant-negative is the working hypothesis.
3. Gain-of-Function
- Mechanism: The mutant protein gains a new activity, increased activity, or a new substrate.
- Variant types: highly recurrent missense variants, often at the same residue (e.g., FGFR3 G380R in achondroplasia).
- Examples: FGFR3 (achondroplasia, hypochondroplasia, thanatophoric dysplasia), RAS / RAF / MEK pathway in RASopathies (Noonan, Costello, CFC), KCNQ1/KCNH2 gain-of-function in Long QT, SCN1A gain-of-function in epilepsies.
4. Toxic Gain-of-Function (Aggregate / Misfolded Protein)
- Mechanism: The mutant protein acquires a toxic property, typically misfolding and aggregating, which damages the cell.
- Examples: Huntingtin (HTT) polyglutamine expansion in HD; α-synuclein in dominant Parkinson's; SOD1 in some ALS; prion proteins.
| Question | Haploinsufficiency | Dominant-negative |
|---|---|---|
| Variant spectrum | Mostly null (nonsense, frameshift, deletion) | Mostly missense in critical domain |
| Heterozygous null severity | Disease (the disease state) | Often milder than missense (or no disease) |
| Whole-gene deletion | Causes disease | May cause milder or no disease |
| Therapeutic angle | Augmentation: gene therapy adding more protein, mRNA therapy, read-through agents (for nonsense variants) | Silencing: ASOs, siRNA, CRISPR knockdown of the mutant allele specifically |
| Penetrance/expressivity | Often correlated with allele dose | Often more variable, modifier-dependent |
- Null is milder than missense → dominant-negative is the mechanism. Counterintuitive but classic. OI type I (null COL1A1, mild) vs OI type II/III/IV (missense COL1A1, severe) is the textbook example.
- Whole-gene deletion phenotype mirrors loss-of-function. If 1p36 deletion phenocopies the syndrome caused by point mutations in a gene there, that gene is haploinsufficient.
- Haploinsufficient + tumor suppressor = germline first hit. Knudson's two-hit model: the inherited haploinsufficient allele is the first hit; a somatic second hit in the wild-type allele in a target tissue triggers the tumor.
- Mechanism predicts therapy. Haploinsufficient → boost protein. Dominant-negative or toxic gain-of-function → eliminate the mutant. Gain-of-function → block the new activity (small-molecule inhibitor). Mechanism is therefore clinically actionable, not just descriptive.
- Same gene, different mechanism, different disease. TP53 has both haploinsufficiency-flavored variants and dominant-negative variants, with different cancer-spectrum implications.
- "All AD diseases are haploinsufficiency": wrong. Many are dominant-negative or gain-of-function. The mechanism predicts the variant spectrum.
- "Loss-of-function and haploinsufficiency are the same thing": almost. Loss-of-function describes the variant; haploinsufficiency describes the gene's tolerance. A loss-of-function variant in a haplosufficient gene causes no disease.
- "Dominant-negative requires a multimeric protein": usually true (collagen, keratin) but not strictly required. Any mutant that physically interferes with wild-type function (sequestering a partner, occupying a substrate site) can be DN.